Metastatic Breast Cancer: [177Lu]Lu-NeoB with Capecitabine

We are studying a new treatment combining [177Lu]Lu-NeoB and capecitabine for adults with specific metastatic breast cancer. The goal is to find the best doses and evaluate how well it works after other treatments have failed.

6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboCost ReimbursementPartially RemoteInvestigational MedicinesOralInjectionEndocrinologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Capecitabine
Capecitabine is a chemotherapy medicine used to treat certain cancers, including breast and colon cancer.
Goserelin Endomedica
Goserelin Endomedica is a medicine that lowers sex hormone levels to treat prostate cancer and some women's reproductive conditions like endometriosis.
Leuprorelin Sandoz
Leuprorelin Sandoz is a hormone-suppressing medicine used to treat prostate cancer, endometriosis, uterine fibroids, and early puberty.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Capecitabine
Capecitabine is a substance that helps stop certain cancers from growing, commonly used for breast and colorectal cancer.
Goserelin
Goserelin is a substance that lowers sex hormone levels to treat hormone-sensitive cancers and conditions.
Leuprorelin
Leuprorelin is a substance that reduces sex hormone production to manage prostate cancer, endometriosis, precocious puberty, and other hormone-related conditions.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Aaa503

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Algonad
Altabactin
Antibiótica Liade

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Institut Bergonie
4006: Medecine Nucleaire
Bordeaux, France
Centre Regional Lutte Contre Le Cancer
4005: Oncologie medicale
Eckbolsheim, France
Centre Hospitalier Universitaire Grenoble Alpes
4004: Medecine Nucleaire
La Tronche, France
Sponsor: Novartis Pharma AG
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.